The role of α-synuclein and LRRK2 in tau phosphorylation

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Kawakami, Fumitaka ^a   Ichikawa, Takafumi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; HEAT SHOCK PROTEIN; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN;

AMINO ACID SEQUENCE; AUTOPHOSPHORYLATION; BRAIN CORTEX; BRAIN REGION; CARBOXY TERMINAL SEQUENCE; CEREBELLUM; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SUBSTANTIA NIGRA; TAU PHOSPHORYLATION; THALAMUS;

EID: 84929353300     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/734746     Document Type: Review

References (93)

1. T. Ishizawa, P. Mattila, P. Davies, D. Wang, and D. W. Dickson, "Colocalization of tau and alpha-synuclein epitopes in Lewy bodies, " Journal ofNeuropathology and ExperimentalNeurology, vol. 62, no. 4, pp. 389-397, 2003.
2. D. W. Dickson, "Neuropathology of non-Alzheimer degenerative disorders, " International Journal of Clinical and Experimental Pathology, vol. 3, no. 1, pp. 1-23, 2010.
3. M. Goedert and M. G. Spillantini, "A century of Alzheimer's disease, " Science, vol. 314, no. 5800, pp. 777-781, 2006.
4. L. I. Binder, A. Frankfurter, and L. I. Rebhun, "The distribution of tau in the mammalian central nervous system, " The Journal of Cell Biology, vol. 101, no. 4, pp. 1371-1378, 1985.
5. R. L. Neve, P. Harris, K. S. Kosik, D. M. Kurnit, andT. A. Donlon, "Identification of cDNA clones for the human microtubuleassociated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2, " Brain Research, vol. 387, no. 3, pp. 271-280, 1986.
6. M. Goedert, M. G. Spillantini, R. Jakes, D. Rutherford, andR. A. Crowther, "Multiple isoforms of humanmicrotubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease, " Neuron, vol. 3, no. 4, pp. 519-526, 1989.
7. A. Andreadis, W. M. Brown, and K. S. Kosik, "Structure and novel exons of the human tau gene, " Biochemistry, vol. 31, no. 43, pp. 10626-10633, 1992.
8. M. Goedert and R. Jakes, "Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization, " The EMBO Journal, vol. 9, no. 13, pp. 4225-4230, 1990.
9. K. S. Kosik, L. D. Orecchio, S. Bakalis, and R. L. Neve, "Developmentally regulated expression of specific tau sequences, " Neuron, vol. 2, no. 4, pp. 1389-1397, 1989.
10. G. Lee, R. L. Neve, and K. S. Kosik, "The microtubule binding domain of tau protein, " Neuron, vol. 2, no. 6, pp. 1615-1624, 1989.
11. N. Hirokawa, Y. Shiomura, and S. Okabe, "Tau proteins: the molecular structure and mode of binding on microtubules, " Journal of Cell Biology, vol. 107, no. 4, pp. 1449-1459, 1988.
12. G. Lee, S. T. Newman, D. L. Gard, H. Band, and G. Panchamoorthy, "Tau interacts with src-family non-receptor tyrosine kinases, " Journal of Cell Science, vol. 111, no. 21, pp. 3167-3177, 1998.
13. J. Avila, J. J. Lucas, M. Pérez, and F. Hernández, "Role of tau protein in both physiological and pathological conditions, " Physiological Reviews, vol. 84, no. 2, pp. 361-384, 2004.
14. L. Martin, X. Latypova, and F. Terro, "Post-translational modifications of tau protein: implications for Alzheimer's disease, " Neurochemistry International, vol. 58, no. 4, pp. 458-471, 2011.
15. J. Avila, E. Gómez De Barreda, T. Engel, J. J. Lucas, and F. Hernández, "Tau phosphorylation in hippocampus results in toxic gain-of-function, " Biochemical Society Transactions, vol. 38, no. 4, pp. 977-980, 2010.
16. R. Godemann, J. Biernat, E. Mandelkow, and E.-M. Mandelkow, "Phosphorylation of tau protein by recombinant GSK-3: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain, " FEBS Letters, vol. 454, no. 1-2, pp. 157-164, 1999.
17. T. Maas, J. Eidenmüller, and R. Brandt, "Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments, " The Journal of Biological Chemistry, vol. 275, no. 21, pp. 15733-15740, 2000.
18. U. Wagner, M. Utton, J.-M. Gallo, and C. C. J. Miller, "Cellular phosphorylation of tau by GSK-3 influences tau binding to microtubules and microtubule organisation, " Journal of Cell Science, vol. 109, no. 6, pp. 1537-1543, 1996.
19. F. Kawakami, N. Shimada, E. Ohta et al. , "Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3, " FEBS Journal, vol. 281, no. 1, pp. 3-13, 2014.
20. F. Kawakami, T. Yabata, E. Ohta et al. , "LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth, " PLoS ONE, vol. 7, no. 1, Article ID e30834, 2012.
21. F. Kawakami, M. Suzuki, N. Shimada et al. , "Stimulatory effect of-synuclein on the tau-phosphorylation by GSK-3, " The FEBS Journal, vol. 278, no. 24, pp. 4895-4904, 2011.
22. C. Lavedan, "The synuclein family, " Genome Research, vol. 8, no. 9, pp. 871-880, 1998.
23. F. Cheng, G. Vivacqua, and S. Yu, "Therole of alpha-synuclein in neurotransmission and synaptic plasticity, " Journal of Chemical Neuroanatomy, vol. 42, no. 4, pp. 242-248, 2011.
24. A. Iwai, E. Masliah, M. Yoshimoto et al. , "The precursor protein of non-A component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, " Neuron, vol. 14, no. 2, pp. 467-475, 1995.
25. E. Rockenstein, L. A. Hansen, M. Mallory, J. Q. Trojanowski, D. Galasko, and E. Masliah, "Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease, " Brain Research, vol. 914, no. 1-2, pp. 48-56, 2001.
26. L. Devi, V. Raghavendran, B. M. Prabhu, N. G. Avadhani, and H. K. Anandatheerthavarada, "Mitochondrial import and accumulation of-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain, " The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9089-9100, 2008.
27. M. Robotta, H. R. Gerding, A. Vogel et al. , "Alpha-synuclein binds to the inner membrane of mitochondria in an-helical conformation, " ChemBioChem, vol. 15, no. 17, pp. 2499-2502, 2014.
28. W. S. Davidson, A. Jonas, D. F. Clayton, and J. M. George, "Stabilization of-synuclein secondary structure upon binding to synthetic membranes, " The Journal of Biological Chemistry, vol. 273, no. 16, pp. 9443-9449, 1998.
29. M. M. Tompkins, W. P. Gai, S. Douglas, and S. J. Bunn, "-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells, " Brain Research, vol. 984, no. 1-2, pp. 233-236, 2003.
30. J. Burré, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton, and T. C. Südhof, "-Synuclein promotes SNARE-complex assembly in vivo and in vitro, " Science, vol. 329, no. 5999, pp. 1663-1667, 2010.
31. M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, "-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6469-6473, 1998.
32. H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, "Staging of brain pathology related to sporadic Parkinson's disease, " Neurobiology of Aging, vol. 24, no. 2, pp. 197-211, 2003.
33. H. Braak, R. A. I. de Vos, J. Bohl, and K. Del Tredici, "Gastric-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's diseaserelated brain pathology, " Neuroscience Letters, vol. 396, no. 1, pp. 67-72, 2006.
34. M. Goedert, "Alpha-synuclein and neurodegenerative diseases, " Nature Reviews Neuroscience, vol. 2, no. 7, pp. 492-501, 2001.
35. T. L. Edwards, W. K. Scott, C. Almonte et al. , "Genome-Wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for parkinson disease, " Annals of Human Genetics, vol. 74, no. 2, pp. 97-109, 2010.
36. J. Simón-Sánchez, C. Schulte, J. M. Bras et al. , "Genome-wide association study reveals genetic risk underlying Parkinson's disease, " Nature Genetics, vol. 41, no. 12, pp. 1308-1312, 2009.
37. K. Arima, T. Mizutani, M. A. Alim et al. , "NACP/-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies, " Acta Neuropathologica, vol. 100, no. 2, pp. 115-121, 2000.
38. J. B. Leverenz, I. Umar, Q. Wang et al. , "Proteomic identification of novel proteins in cortical Lewy bodies, " Brain Pathology, vol. 17, no. 2, pp. 139-145, 2007.
39. A. Esposito, C. P. Dohm, P. Kermer, M. Bähr, and F. S. Wouters, "-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton, " Neurobiology of Disease, vol. 26, no. 3, pp. 521-531, 2007.
40. T. Duka, M. Rusnak, R. E. Drolet et al. , "Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism, " The FASEB Journal, vol. 20, no. 13, pp. 2302-2312, 2006.
41. P. H. Jensen, H. Hager, M. S. Nielsen, P. Højrup, J. Gliemann, and R. Jakes, "-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356, "The Journal of Biological Chemistry, vol. 274, no. 36, pp. 25481-25489, 1999.
42. T. Duka, V. Duka, J. N. Joyce, and A. Sidhu, "-synuclein contributes to GSK-3-catalyzed Tau phosphorylation in Parkinson's disease models, " The FASEB Journal, vol. 23, no. 9, pp. 2820-2830, 2009.
43. R. V. Bhat, S. L. B. Haeberlein, and J. Avila, "Glycogen synthase kinase 3:adrug target forCNS therapies, " Journal ofNeurochemistry, vol. 89, no. 6, pp. 1313-1317, 2004.
44. W. Li, C. Lesuisse, Y. Xu, J. C. Troncoso, D. L. Price, and M. K. Lee, "Stabilization of-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation, " Journal of Neuroscience, vol. 24, no. 33, pp. 7400-7409, 2004.
45. K. Beyer, M. Domingo-Sàbat, C. Santos, E. Tolosa, I. Ferrer, and A. Ariza, "The decrease of-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies, " Brain, vol. 133, no. 12, pp. 3724-3733, 2010.
46. A. L. Biere, S. J. Wood, J. Wypych et al. , "Parkinson's diseaseassociated-synuclein is more fibrillogenic than-and-synuclein and cannot cross-seed its homologs, " The Journal of Biological Chemistry, vol. 275, no. 44, pp. 34574-34579, 2000.
47. I. M. J. Segers-Nolten, M. M. M. Wilhelmus, G. Veldhuis, B. D. Van Rooijen, B. Drukarch, and V. Subramaniam, "Tissue transglutaminasemodulates-synuclein oligomerization, " Protein Science, vol. 17, no. 8, pp. 1395-1402, 2008.
48. K. A. Butner and M. W. Kirschner, "Tau protein binds to microtubules through a flexible array of distributed weak sites, " The Journal of Cell Biology, vol. 115, no. 3, pp. 717-730, 1991.
49. S. Khatoon, I. Grundke-Iqbal, and K. Iqbal, "Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein, " Journal of Neurochemistry, vol. 59, no. 2, pp. 750-753, 1992.
50. C. Paisán-Rúz, S. Jain, E. W. Evans et al. , "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, " Neuron, vol. 44, no. 4, pp. 595-600, 2004.
51. A. Zimprich, S. Biskup, P. Leitner et al. , "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, " Neuron, vol. 44, no. 4, pp. 601-607, 2004.
52. S. Lesage and A. Brice, "Parkinson's disease: from monogenic forms to genetic susceptibility factors, " Human Molecular Genetics, vol. 18, no. 1, pp. R48-R59, 2009.
53. C. A. Davie, "A review of Parkinson's disease, " British Medical Bulletin, vol. 86, no. 1, pp. 109-127, 2008.
54. I. F. Mata, W. J. Wedemeyer, M. J. Farrer, J. P. Taylor, and K. A. Gallo, "LRRK2 in Parkinson's disease: protein domains and functional insights, " Trends in Neurosciences, vol. 29, no. 5, pp. 286-293, 2006.
55. J. R. Adams, H. Van Netten, M. Schulzer et al. , "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation, " Brain, vol. 128, no. 12, pp. 2777-2785, 2005.
56. L. V. Kalia, A. E. Lang, L. N. Hazrati et al. , "Clinical correlations with lewy body pathology in LRRK2-related Parkinson disease, " JAMA Neurology, vol. 72, no. 1, pp. 100-105, 2015.
57. R. D. Mills, T. D. Mulhern, F. Liu, J. G. Culvenor, and H. C. Cheng, "Prediction of the repeat domain structures and impact of Parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2), " Human Mutation, vol. 35, no. 4, pp. 395-412, 2014.
58. A. B. West, D. J. Moore, S. Biskup et al. , "Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 46, pp. 16842-16847, 2005.
59. G. Ito, T. Okai, G. Fujino et al. , "GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease, " Biochemistry, vol. 46, no. 5, pp. 1380-1388, 2007.
60. J.-M. Taymans, R. Vancraenenbroeck, P. Ollikainen et al. , "LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding, " PLoS ONE, vol. 6, no. 8, Article ID e23207, 2011.
61. E. Greggio, I. Zambrano, A. Kaganovich et al. , "The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation, " The Journal of Biological Chemistry, vol. 283, no. 24, pp. 16906-16914, 2008.
62. S. Sen, P. J. Webber, and A. B. West, "Leucine-rich repeat kinase 2 (LRRK2) kinase activity: dependence on dimerization, " The Journal of Biological Chemistry, vol. 284, no. 52, pp. 36346-36356, 2009.
63. Z. Berger, K. A. Smith, andM. J. Lavoie, "Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation, " Biochemistry, vol. 49, no. 26, pp. 5511-5523, 2010.
64. J. Simón-Sánchez, V. Herranz-Pérez, F. Olucha-Bordonau, and J. Pérez-Tur, "LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain, " European Journal of Neuroscience, vol. 23, no. 3, pp. 659-666, 2006.
65. M. R. Cookson, "The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, " Nature Reviews Neuroscience, vol. 11, no. 12, pp. 791-797, 2010.
66. E. Lobbestael, V. Baekelandt, and J.-M. Taymans, "Phosphorylation of LRRK2: from kinase to substrate, " Biochemical Society Transactions, vol. 40, no. 5, pp. 1102-1110, 2012.
67. G. Skibinski, K. Nakamura, M. R. Cookson, and S. Finkbeiner, "Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies, " Journal of Neuroscience, vol. 34, no. 2, pp. 418-433, 2014.
68. S. Ujiie, T. Hatano, S.-I. Kubo et al. , "LRRK2 I2020T mutation is associated with tau pathology, " Parkinsonism & Related Disorders, vol. 18, no. 7, pp. 819-823, 2012.
69. R. M. Bailey, J. P. Covy, H. L. Melrose et al. , "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy, " Acta Neuropathologica, vol. 126, no. 6, pp. 809-827, 2013.
70. H. L. Melrose, J. C. Dächsel, B. Behrouz et al. , "Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice, " Neurobiology of Disease, vol. 40, no. 3, pp. 503-517, 2010.
71. C. Ruffmann, G. Giaccone, M. Canesi et al. , "Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremordominant Parkinsonism, " Neuropathology and Applied Neurobiology, vol. 38, no. 4, pp. 382-386, 2012.
72. Y. Li, W. Liu, T. F. Oo et al. , "Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease, " Nature Neuroscience, vol. 12, no. 7, pp. 826-828, 2009.
73. A. Rajput, D. W. Dickson, C. A. Robinson et al. , "Parkinsonism, Lrrk2 G2019S, and tau neuropathology, " Neurology, vol. 67, no. 8, pp. 1506-1508, 2006.
74. F. Gillardon, "Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in Parkinsonian neurodegeneration" Journal of Neurochemistry, vol. 110, no. 5, pp. 1514-1522, 2009.
75. C.-H. Lin, P.-I. Tsai, R.-M. Wu, and C.-T. Chien, "LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3, " The Journal of Neuroscience, vol. 30, no. 39, pp. 13138-13149, 2010.
76. E. Ohta, F. Kawakami, M. Kubo, and F. Obata, "LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's diseaseassociated mutations, " FEBS Letters, vol. 585, no. 14, pp. 2165-2170, 2011.
77. A. Di Fonzo, Y.-H. Wu-Chou, C.-S. Lu et al. , "A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan, " Neurogenetics, vol. 7, no. 3, pp. 133-138, 2006.
78. M. Funayama, Y. Li, H. Tomiyama et al. , "Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population, " NeuroReport, vol. 18, no. 3, pp. 273-275, 2007.
79. X.-K. An, R. Peng, T. Li et al. , "LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China, " European Journal of Neurology, vol. 15, no. 3, pp. 301-305, 2008.
80. J.-M. Kim, J.-Y. Lee, H. J. Kim et al. , "The LRRK2G2385Rvariant is a risk factor for sporadic Parkinson's disease in the Korean population, " Parkinsonism and Related Disorders, vol. 16, no. 2, pp. 85-88, 2010.
81. S. Zach, S. Felk, and F. Gillardon, "Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity, " PLoS ONE, vol. 5, no. 10, Article ID e13191, 2010.
82. M. P. Mayer and B. Bukau, "Hsp70 chaperones: cellular functions and molecular mechanism, " Cellular and Molecular Life Sciences, vol. 62, no. 6, pp. 670-684, 2005.
83. M. Lichtenberg, A. Mansilla, V. R. Zecchini, A. Fleming, and D. C. Rubinsztein, "The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity, " Cell Death & Disease, vol. 2, no. 8, article e196, 2011.
84. L. Petrucelli, D. Dickson, K. Kehoe et al. , "CHIP andHsp70 regulate tau ubiquitination, degradation and aggregation, " Human Molecular Genetics, vol. 13, no. 7, pp. 703-714, 2004.
85. C. J. Gloeckner, N. Kinkl, A. Schumacher et al. , "The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity, " Human Molecular Genetics, vol. 15, no. 2, pp. 223-232, 2006.
86. L. Wang, C. Xie, E. Greggio et al. , "The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2, " Journal of Neuroscience, vol. 28, no. 13, pp. 3384-3391, 2008.
87. W. Noble, E. Planel, C. Zehr et al. , "Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6990-6995, 2005.
88. A. Macdonald, K. Briggs, M. Poppe, A. Higgins, L. Velayudhan, and S. Lovestone, "A feasibility and tolerability study of lithium in Alzheimer's disease, " International Journal of Geriatric Psychiatry, vol. 23, no. 7, pp. 704-711, 2008.
89. A. Ali, K. P. Hoeflich, and J. R. Woodgett, "Glycogen synthase kinase-3: properties, functions, and regulation, " Chemical Reviews, vol. 101, no. 8, pp. 2527-2540, 2001.
90. M. M. Dedmon, J. Christodoulou, M. R. Wilson, and C. M. Dobson, "Heat shock protein 70 inhibits-synuclein fibril formation via preferential binding to prefibrillar species, " Journal of Biological Chemistry, vol. 280, no. 15, pp. 14733-14740, 2005.
91. R. C. Lu, M. S. Tan, H. Wang, A. M. Xie, J. T. Yu, and L. Tan, "Heat shock protein 70 inAlzheimer's disease, " BioMed Research International, vol. 2014, Article ID 435203, 8 pages, 2014.
92. S. R. Choi, S. A. Lee, Y. J. Kim, C. Y. Ok, H. J. Lee, and K. B. Hahm, "Role of heat shock proteins in gastric inflammation and ulcer healing, " Journal of Physiology and Pharmacology, vol. 60, no. 7, pp. 5-17, 2009.
93. D. M. Taylor, M. L. Tradewell, S. Minotti, and H. D. Durham, "Characterizing the role of Hsp90 in production of heat shock proteins in motor neurons reveals a suppressive effect of wildtypeHsf1, " Cell Stress Chaperones, vol. 12, no. 2, pp. 151-162, 2007.